Compliance, Medication, Rhinitis, Allergic
Conditions
Keywords
allergic rhinitis, Intranasal steroid spray, compliance, mobile alarm
Brief summary
This is a randomized controlled trial to compare the compliance of allergic rhinitis patients towards intranasal steroids between those who use mobile daily alarm reminder and those who do not.
Detailed description
In this single blinded RCT, adults with allergic rhinitis are randomized into either he intervention or control arm. The intervention involves installing an alarm with a prerecorded nmessage Have you take your intranasal steroids which will automatically ring every day on the patients mobile phone. The control arm do not have any alarm set up. Both groups are offered counseling and education regarding the importance of compliance to intranasal steroid upon recruitment. Daily reminder to take medication may eliminate reason for forgetting medication schedule, hence, improve compliance towards INCS among patients with allergic rhinitis. This study aims to assess the effectiveness of using daily mobile alarm on patient's compliance towards INCS.
Interventions
OTHERMobile phone alarm reminder
Patients are reminded to take their INCS using a mobile phone alarm set to ring daily
Sponsors
Glenmark Pharmaceuticals S.A.
National University of Malaysia
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)
Masking description
The participant will be assigned a study number based on the recruitment timeline and assigned into the pre-randomized groups. Throughout the study, the primary investigator will not know which group is assigned for the mobile phone daily alarm. A second investigator will select the group for mobile phone daily alarm and set the alarm.
Intervention model description
Single blinded randomized controlled trial
Eligibility
Sex/Gender
ALL
Age
15 Years to 66 Years
Healthy volunteers
No
Inclusion criteria
* • Patients aged 15 years old to 60 years old with persistent AR * Positive SPT towards DF, DP, BT, cockroach, Aspergillus, Cat fur * Own and able to operate functioning mobile smartphone with built in alarm * Able to understand simple instructions * Patients who can read in English and Malay * Newly diagnosed AR or previous patients who only take intranasal corticosteroid less than 4 times per week
Exclusion criteria
* • Patients on immunotherapy * Patients with mild intermittent AR * Pregnant patients * Patient with psychiatric illness * Patients with gross anatomical obstruction (severe DNS, gross polyposis, nasal tumour) * Chronic rhinosinusitis(CRS) with or without nasal polyposis * Patients who have adverse reaction towards INCS * Patients with severe hearing loss
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compliance | 30 days | Compliance was taken as 2/3rd use of INCS (20 days out of 30) = 20 x 0.38 = 7.6 g reduced weight. |
Countries
Malaysia
Outcome results
None listed